Takeda to partner on patient-centric data with SeqsterTakeda has partnered with patient data firm Seqster in a drive to improve care through better access and Share XTakeda to partner on patient-centric data with Seqsterhttps://pharmaphorum.com/news/takeda-to-partner-on-patient-centric-data-with-seqster/
Takeda’s bleeding disorder drug Veyvondi backed for NHS useNHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it Share XTakeda’s bleeding disorder drug Veyvondi backed for NHS usehttps://pharmaphorum.com/news/takedas-bleeding-disorder-drug-veyvondi-backed-for-nhs-use/
Janssen files Darzalex Faspro for rare disease light chain amyloidosisJanssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal Share XJanssen files Darzalex Faspro for rare disease light chain amyloidosishttps://pharmaphorum.com/news/janssen-files-new-darzalex-for-rare-disease-light-chain-amyloidosis/
Despite biosims, ulcerative colitis drugs still cost too much; ICERNone of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough Share XDespite biosims, ulcerative colitis drugs still cost too much; ICERhttps://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/
Takeda agrees $2.3bn sale of Japanese consumer health unitTakeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on Share XTakeda agrees $2.3bn sale of Japanese consumer health unithttps://pharmaphorum.com/news/takeda-agrees-2-3bn-sale-of-japanese-consumer-health-unit/
Roche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outRoche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans Share XRoche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outhttps://pharmaphorum.com/news/roches-ulcerative-colitis-drug-etrolizumab-looks-shaky-after-data-roll-out/
NICE backs NHS use of Takeda’s Adcetris for rare blood cancerTakeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form Share XNICE backs NHS use of Takeda’s Adcetris for rare blood cancerhttps://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/
Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
